• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name:  Phosphorodiamidate morpholino oligomer (5’- CTATATATAGTTATTCAACA -3’)
Trade Name:  N/A
Date Designated:  03/04/2020
Orphan Designation:  Treatment of Spinal Muscular Atrophy
Orphan Designation Status:  Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Marketing Approval Date:  N/A
Approved Labeled Indication:  
Exclusivity End Date:    N/A
Exclusivity Protected Indication*:  
Shift Pharmaceuticals Holdings, Inc.
8318 West 102nd Street
Overland Park, Kansas 66212

The sponsor address listed is the last reported by the sponsor to OOPD.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.